Explore JDDonline If you’re on the hunt for expert-led, handpicked resources on atopic dermatitis, you’re in the right place. Whether you're brushing up on the latest treatment insights or looking…
Read More
Are Atopic Dermatitis Clinical Trials Becoming More Inclusive? Atopic dermatitis (AD) affects over 31 million people in the U.S., disproportionately impacting racial and ethnic minorities who often experience greater disease…
Read More
Dupilumab Treatment Improves Lichenification in Atopic Dermatitis in Different Age and Racial Groups
JDD Spotlight: Dupilumab Shows Rapid, Sustained Relief for Lichenification in AD A new pooled analysis from five clinical trials has revealed that dupilumab significantly improves lichenification in moderate to severe…
Read More
By Allison Sit The American Academy of Dermatology (AAD) is joining with other specialties in speaking out about cuts to the Medicare Physician Fee Schedule for 2025. The physician services…
Read More
JDD Article Highlights Vitiligo research is often inconsistent when it comes to measuring disease severity, making it challenging to compare treatment outcomes. The IDEOM Vitiligo Workgroup has begun efforts to…
Read More
Cleansing is a significant daily hygiene step used by many to fight against infections and keep the skin healthy. However, cleansing also presents new challenges in the face of skin…
Read More
JDD Video Exclusive At the recent Revolutionizing Atopic Dermatitis (RAD) conference, Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health,…
Read More
By Allison Sit Semaglutide – a glucagon-like peptide (GLP)-1RA – improved outcomes for obese patients with hidradenitis suppurativa (HS), according to a study presented at EADV Congress 2024. The study…
Read More
By Allison Sit A National Eczema Association (NEA) study published in JAMA Dermatology identified patient-reported attributes associated with a “flare” of atopic dermatitis. The study sought to develop a clearer…
Read More
by Allison Sit Healio wrote about two JDD studies on psoriasis treatments including one on the benefits of long-term ixekizumab. The study, “Benefits Over Five Years of Ixekizumab Treatment in…
Read More
by Allison Sit Managed Healthcare Executive and Healio both wrote about a JDD study on the underrepresentation of racial and ethnic minority groups in vitiligo research. The study, “Racial and…
Read More
by Allison Sit Dermatology Times, HAPPI, Healio and HealthDay all wrote about an April article in the Journal of Drugs in Dermatology that was one of one of the largest,…
Read More
